Advertisement

Considerations for Imaging of Malignant Pleural Mesothelioma: A Consensus Statement from the International Mesothelioma Interest Group

Published:December 19, 2022DOI:https://doi.org/10.1016/j.jtho.2022.11.018

      Abstract

      Malignant pleural mesothelioma (MPM) is an aggressive primary malignancy of the pleura that presents unique radiologic challenges with regard to accurate and reproducible assessment of disease extent at staging and follow-up imaging. By optimizing and harmonizing technical approaches to imaging MPM, the best quality imaging can be achieved for individual patient care, clinical trials, and imaging research. This consensus statement represents agreement on harmonized, standard practices for routine multimodality imaging of MPM, including radiography, computed tomography, 18F-2-deoxy-D-glucose positron emission tomography, and magnetic resonance imaging, by an international panel of experts in the field of pleural imaging assembled by the International Mesothelioma Interest Group. In addition, modality-specific technical considerations and future directions are discussed. A bulleted summary of all technical recommendations is provided.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Attanoos R.L.
        • Churg A.
        • Galateau-Salle F.
        • Gibbs A.R.
        • Roggli V.L.
        Malignant mesothelioma and its non-asbestos causes.
        Arch Pathol Lab Med. 2018; 142: 753-760
        • Henley S.J.
        • Larson T.C.
        • Wu M.
        • et al.
        Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008.
        Int J Occup Environ Health. 2013; 19: 1-10
        • Prüss-Ustün A.
        • Vickers C.
        • Haefliger P.
        • Bertollini R.
        Knowns and unknowns on burden of disease due to chemicals: a systematic review.
        Environ Health. 2011; 10: 9
        • Odgerel C.O.
        • Takahashi K.
        • Sorahan T.
        • et al.
        Estimation of the global burden of mesothelioma deaths from incomplete national mortality data.
        Occup Environ Med. 2017; 74: 851-858
        • Delgermaa V.
        • Takahashi K.
        • Park E.K.
        • Le G.V.
        • Hara T.
        • Sorahan T.
        Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008.
        Bull World Health Organ. 2011; 89: 716-724C
        • Tsao A.S.
        • Lindwasser O.W.
        • Adjei A.A.
        • et al.
        Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.
        J Thorac Oncol. 2018; 13: 1655-1667
        • Woodard G.A.
        • Jablons D.M.
        Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma.
        Transl Lung Cancer Res. 2020; 9: S86-S91
        • de Gooijer C.J.
        • Borm F.J.
        • Scherpereel A.
        • Baas P.
        Immunotherapy in malignant pleural mesothelioma.
        Front Oncol. 2020; 10: 187
        • Nicolini F.
        • Bocchini M.
        • Bronte G.
        • et al.
        Malignant pleural mesothelioma: state-of-the-art on current therapies and promises for the future.
        Front Oncol. 2020; 9: 1519
        • Røe O.D.
        Mesothelioma diagnosis and prognosis, are we moving beyond histology and performance status towards circulating biomarkers?.
        J Thorac Dis. 2018; 10: S1956-S1961
        • Enewold L.
        • Sharon E.
        • Thomas A.
        Patterns of care and survival among patients with malignant mesothelioma in the United States.
        Lung Cancer. 2017; 112: 102-108
        • Flores R.M.
        • Pass H.I.
        • Seshan V.E.
        • et al.
        Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
        J Thorac Cardiovasc Surg. 2008; 135 (e6263): 620-626
        • Burt B.M.
        • Richards W.G.
        • Lee H.S.
        • et al.
        A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma.
        J Thorac Oncol. 2018; 13: 1400-1409
        • Hallifax R.J.
        • Haris M.
        • Corcoran J.P.
        • et al.
        Role of CT in assessing pleural malignancy prior to thoracoscopy.
        Thorax. 2015; 70: 192-193
        • Tsim S.
        • Stobo D.B.
        • Alexander L.
        • Kelly C.
        • Blyth K.G.
        The diagnostic performance of routinely acquired and reported computed tomography imaging in patients presenting with suspected pleural malignancy.
        Lung Cancer. 2017; 103: 38-43
        • Gill R.R.
        • Tsao A.S.
        • Kindler H.L.
        • et al.
        Radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials: consensus statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.
        J Thorac Oncol. 2019; 14: 1718-1731
        • Helm E.J.
        • Matin T.N.
        • Gleeson F.V.
        Imaging of the pleura.
        J Magn Reson Imaging. 2010; 32: 1275-1286
        • Beckett P.
        • Edwards J.
        • Fennell D.
        • Hubbard R.
        • Woolhouse I.
        • Peake M.D.
        Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales.
        Lung Cancer. 2015; 88: 344-348
        • Adams V.I.
        • Unni K.K.
        • Muhm J.R.
        • Jett J.R.
        • Ilstrup D.M.
        • Bernatz P.E.
        Diffuse malignant mesothelioma of pleura. Diagnosis and survival in 92 cases.
        Cancer. 1986; 58: 1540-1551
        • Salonen O.
        • Kivisaari L.
        • Standertskjöld-Nordenstam C.G.
        • Somer K.
        • Mattson K.
        • Tammilehto L.
        Computed tomography of pleural lesions with special reference to the mediastinal pleura.
        Acta Radiol Diagn (Stockh). 1986; 27: 527-531
        • Pairon J.C.
        • Laurent F.
        • Rinaldo M.
        • et al.
        Pleural plaques and the risk of pleural mesothelioma.
        J Natl Cancer Inst. 2013; 105: 293-301
        • Paris C.
        • Thierry S.
        • Brochard P.
        • et al.
        Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data.
        Eur Respir J. 2009; 34: 72-79
        • Steiner R.M.
        • Cooper M.W.
        • Brodovsky H.
        Rib destruction: a neglected finding in malignant mesothelioma.
        Clin Radiol. 1982; 33: 61-65
        • Ueda D.
        • Yamamoto A.
        • Shimazaki A.
        • et al.
        Artificial intelligence-supported lung cancer detection by multi-institutional readers with multi-vendor chest radiographs: a retrospective clinical validation study.
        BMC Cancer. 2021; 21: 1120
        • Homayounieh F.
        • Digumarthy S.
        • Ebrahimian S.
        • et al.
        An artificial intelligence-based chest X-ray model on human nodule detection accuracy from a multicenter study.
        JAMA Netw Open. 2021; 4e2141096
        • Gill R.R.
        • Richards W.G.
        • Yeap B.Y.
        • et al.
        Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
        AJR Am J Roentgenol. 2012; 198: 359-363
        • Travis W.D.
        • Asamura H.
        • Bankier A.A.
        • et al.
        The IASLC lung cancer staging project: proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer.
        J Thorac Oncol. 2016; 11: 1204-1223
        • Oh J.K.
        • Ahn M.I.
        • Kim H.L.
        • Park S.H.
        • Shin E.
        Retrodiaphragmatic portion of the lung: how deep is the posterior costophrenic sulcus on posteroanterior chest radiography?.
        Clin Radiol. 2009; 64: 786-791
        • Corcoran J.P.
        • Acton L.
        • Ahmed A.
        • et al.
        Diagnostic value of radiological imaging pre- and post-drainage of pleural effusions.
        Respirology. 2016; 21: 392-395
        • Clive A.O.
        • Wilson P.
        • Taylor H.
        • et al.
        Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases.
        BMJ Open. 2015; 5e006673
        • Patel A.
        • Roshkovan L.
        • McNulty S.
        • et al.
        Delayed-phase enhancement for evaluation of malignant pleural mesothelioma on computed tomography: a prospective cohort study.
        Clin Lung Cancer. 2021; 22: 210-217.e1
        • Raj V.
        • Kirke R.
        • Bankart M.J.
        • Entwisle J.J.
        Multidetector CT imaging of pleura: comparison of two contrast infusion protocols.
        Br J Radiol. 2011; 84: 796-799
        • Iezzi R.
        • Larici A.R.
        • Franchi P.
        • et al.
        Tailoring protocols for chest CT applications: when and how?.
        Diagn Interv Radiol. 2017; 23: 420-427
        • Bhalla A.S.
        • Das A.
        • Naranje P.
        • Irodi A.
        • Raj V.
        • Goyal A.
        Imaging protocols for CT chest: a recommendation.
        Indian J Radiol Imaging. 2019; 29: 236-246
        • Tsim S.
        • Humphreys C.A.
        • Cowell G.W.
        • et al.
        Early contrast enhancement: a novel magnetic resonance imaging biomarker of pleural malignancy.
        Lung Cancer. 2018; 118: 48-56
        • Prezzi D.
        • Khan A.
        • Goh V.
        Perfusion CT imaging of treatment response in oncology.
        Eur J Radiol. 2015; 84: 2380-2385
        • Blomley M.J.
        • Coulden R.
        • Bufkin C.
        • Lipton M.J.
        • Dawson P.
        Contrast bolus dynamic computed tomography for the measurement of solid organ perfusion.
        Invest Radiol. 1993; 28: S72-S78
        • Sudarski S.
        • Shi J.
        • Schmid-Bindert G.
        • et al.
        Dynamic volume perfusion computed tomography parameters versus RECIST for the prediction of outcome in lung cancer patients treated with conventional chemotherapy.
        J Thorac Oncol. 2015; 10: 164-171
        • Yang L.
        • Zhang X.M.
        • Tan B.X.
        • Liu M.
        • Dong G.L.
        • Zhai Z.H.
        Computed tomographic perfusion imaging for the therapeutic response of chemoembolization for hepatocellular carcinoma.
        J Comput Assist Tomogr. 2012; 36: 226-230
        • Meijerink M.R.
        • van Cruijsen H.
        • Hoekman K.
        • et al.
        The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.
        Eur Radiol. 2007; 17: 1700-1713
        • Gudmundsson E.
        • Labby Z.
        • Straus C.M.
        • et al.
        Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study.
        Eur Radiol. 2019; 29: 682-688
        • Lennartz S.
        • Le Blanc M.
        • Zopfs D.
        • et al.
        Dual-energy CT-derived iodine maps: use in assessing pleural carcinomatosis.
        Radiology. 2019; 290: 796-804
        • Odisio E.G.
        • Truong M.T.
        • Duran C.
        • de Groot P.M.
        • Godoy M.C.
        Role of dual-energy computed tomography in thoracic oncology.
        Radiol Clin North Am. 2018; 56: 535-548
        • Zhang X.
        • Duan H.
        • Yu Y.
        • et al.
        Differential diagnosis between benign and malignant pleural effusion with dual-energy spectral CT.
        PLoS One. 2018; 13e0193714
        • Nowak A.K.
        • Francis R.J.
        • Phillips M.J.
        • et al.
        A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
        Clin Cancer Res. 2010; 16: 2409-2417
        • Wang Y.
        • Carter B.W.
        • Muse V.
        • Digumarthy S.
        • Shepard J.A.
        • Sharma A.
        Potential pitfall in the assessment of lung cancer with FDG-PET/CT: talc pleurodesis causes intrathoracic nodal FDG avidity.
        Lung Cancer Int. 2013; 2013: 683582
        • Nowak A.K.
        • Francis R.J.
        • Katz S.I.
        • Gerbaudo V.H.
        A multimodality imaging review of malignant pleural mesothelioma response assessment.
        PET Clin. 2011; 6: 299-311
        • Boellaard R.
        • O’Doherty M.J.
        • Weber W.A.
        • et al.
        FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0.
        Eur J Nucl Med Mol Imaging. 2010; 37: 181-200
        • Boellaard R.
        • Delgado-Bolton R.
        • Oyen W.J.
        • et al.
        FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0.
        Eur J Nucl Med Mol Imaging. 2015; 42: 328-354
        • American College of Radiology
        ACR–ACNM–SNMMI–SPR practice parameter for performing FDG-PET/CT in oncology.
        (Accessed XXX)
        • Zucali P.A.
        • Lopci E.
        • Ceresoli G.L.
        • et al.
        Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
        Cancer Med. 2017; 6: 2287-2296
        • Francis R.J.
        • Byrne M.J.
        • van der Schaaf A.A.
        • et al.
        Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
        J Nucl Med. 2007; 48: 1449-1458
        • Rusch V.W.
        A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
        Lung Cancer. 1996; 14: 1-12
        • Murphy D.J.
        • Mak S.M.
        • Mallia A.
        • et al.
        Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI.
        Eur J Radiol. 2019; 115: 46-52
        • Francis R.J.
        • Segard T.
        • Morandeau L.
        • et al.
        Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT.
        Lung Cancer. 2015; 90: 55-60
        • Gündoğan C.
        • Güzel Y.
        • Kömek H.
        • Etem H.
        • Kaplan İ.
        68Ga-FAPI-04 PET/CT versus 18F-FDG PET/CT in malignant peritoneal mesothelioma.
        Clin Nucl Med. 2022; 47: e113-e115
        • Patel A.M.
        • Berger I.
        • Wileyto E.P.
        • et al.
        The value of delayed phase enhanced imaging in malignant pleural mesothelioma.
        J Thorac Dis. 2017; 9: 2344-2349
        • Martini K.
        • Meier A.
        • Opitz I.
        • et al.
        Diagnostic accuracy of sequential co-registered PET+MR in comparison to PET/CT in local thoracic staging of malignant pleural mesothelioma.
        Lung Cancer. 2016; 94: 40-45
        • Armato 3rd, S.G.
        • Francis R.J.
        • Katz S.I.
        • et al.
        Imaging in pleural mesothelioma: a review of the 14th International Conference of the International Mesothelioma Interest Group.
        Lung Cancer. 2019; 130: 108-114
        • Heelan R.T.
        • Rusch V.W.
        • Begg C.B.
        • Panicek D.M.
        • Caravelli J.F.
        • Eisen C.
        Staging of malignant pleural mesothelioma: comparison of CT and MR imaging.
        AJR Am J Roentgenol. 1999; 172: 1039-1047
        • Stewart D.
        • Waller D.
        • Edwards J.
        • Jeyapalan K.
        • Entwisle J.
        Is there a role for pre-operative contrast-enhanced magnetic resonance imaging for radical surgery in malignant pleural mesothelioma?.
        Eur J Cardiothorac Surg. 2003; 24: 1019-1024
        • Rudnick M.R.
        • Wahba I.M.
        • Leonberg-Yoo A.K.
        • Miskulin D.
        • Litt H.I.
        Risks and options with gadolinium-based contrast agents in patients with CKD: a review.
        Am J Kidney Dis. 2021; 77: 517-528
        • Ng T.S.C.
        • Seethamraju R.T.
        • Bueno R.
        • Gill R.R.
        Clinical implementation of a free-breathing, motion-robust dynamic contrast-enhanced MRI protocol to evaluate pleural tumors.
        AJR Am J Roentgenol. 2020; 215: 94-104
        • Gill R.R.
        • Umeoka S.
        • Mamata H.
        • et al.
        Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes.
        AJR Am J Roentgenol. 2010; 195: W125-W130
        • Coolen J.
        • De Keyzer F.
        • Nafteux P.
        • et al.
        Malignant pleural mesothelioma: visual assessment by using pleural pointillism at diffusion-weighted MR imaging.
        Radiology. 2015; 274: 576-584
        • Vivoda Tomšič M.
        • Bisdas S.
        • Kovač V.
        • Serša I.
        • Šurlan Popovič K.
        Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria.
        Cancer Imaging. 2019; 19: 10
        • Coolen J.
        • De Keyzer F.
        • Nafteux P.
        • et al.
        Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging--initial experience.
        Radiology. 2012; 263: 884-892
        • Diacon A.H.
        • Brutsche M.H.
        • Solèr M.
        Accuracy of pleural puncture sites: a prospective comparison of clinical examination with ultrasound.
        Chest. 2003; 123: 436-441
        • Grogan D.R.
        • Irwin R.S.
        • Channick R.
        • et al.
        Complications associated with thoracentesis. A prospective, randomized study comparing three different methods.
        Arch Intern Med. 1990; 150: 873-877
        • Weingardt J.P.
        • Guico R.R.
        • Nemcek Jr., A.A.
        • Li Y.P.
        • Chiu S.T.
        Ultrasound findings following failed, clinically directed thoracenteses.
        J Clin Ultrasound. 1994; 22: 419-426
        • Kohan J.M.
        • Poe R.H.
        • Israel R.H.
        • et al.
        Value of chest ultrasonography versus decubitus roentgenography for thoracentesis.
        Am Rev Respir Dis. 1986; 133: 1124-1126
        • Havelock T.
        • Teoh R.
        • Laws D.
        • Gleeson F.
        • BTS Pleural Disease Guideline Group
        Pleural procedures and thoracic ultrasound: British Thoracic Society Pleural Disease Guideline 2010.
        Thorax. 2010; 65: ii61-ii76
        • Görg C.
        • Restrepo I.
        • Schwerk W.B.
        Sonography of malignant pleural effusion.
        Eur Radiol. 1997; 7: 1195-1198
        • Yang P.C.
        • Luh K.T.
        • Chang D.B.
        • Wu H.D.
        • Yu C.J.
        • Kuo S.H.
        Value of sonography in determining the nature of pleural effusion: analysis of 320 cases.
        AJR Am J Roentgenol. 1992; 159: 29-33
        • Wu R.G.
        • Yang P.C.
        • Kuo S.H.
        • Luh K.T.
        “Fluid color” sign: a useful indicator for discrimination between pleural thickening and pleural effusion.
        J Ultrasound Med. 1995; 14: 767-769
        • Qureshi N.R.
        • Rahman N.M.
        • Gleeson F.V.
        Thoracic ultrasound in the diagnosis of malignant pleural effusion.
        Thorax. 2009; 64: 139-143
        • Medford A.R.
        • Agrawal S.
        • Bennett J.A.
        • Free C.M.
        • Entwisle J.J.
        Thoracic ultrasound prior to medical thoracoscopy improves pleural access and predicts fibrous septation.
        Respirology. 2010; 15: 804-808
        • Shojaee S.
        • Lee H.J.
        Thoracoscopy: medical versus surgical—in the management of pleural diseases.
        J Thorac Dis. 2015; 7: S339-S351
        • Byrne M.J.
        • Nowak A.K.
        Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
        Ann Oncol. 2004; 15: 257-260
        • Armato 3rd, S.G.
        • Nowak A.K.
        Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1).
        J Thorac Oncol. 2018; 13: 1012-1021
        • Sensakovic W.F.
        • Starkey A.
        • Roberts R.
        • et al.
        The influence of initial outlines on manual segmentation.
        Med Phys. 2010; 37: 2153-2158
        • Armato 3rd, S.G.
        • Nowak A.K.
        • Francis R.J.
        • Kocherginsky M.
        • Byrne M.J.
        Observer variability in mesothelioma tumor thickness measurements: defining minimally measurable lesions.
        J Thorac Oncol. 2014; 9: 1187-1194
        • Gill R.R.
        • Murphy D.J.
        • Seethamraju R.T.
        • Mazzola E.
        • Bueno R.
        • Richard W.G.
        Interobserver variability of quantitative and qualitative assessment using MRI in malignant pleural mesothelioma.
        Radiol Cardiothorac Imaging. 2020; 2e190066
        • Katz S.I.
        • Hammer M.
        • Bagley S.J.
        • et al.
        Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer.
        J Thorac Oncol. 2018; 13: 978-986
        • Borcoman E.
        • Kanjanapan Y.
        • Champiat S.
        • et al.
        Novel patterns of response under immunotherapy.
        Ann Oncol. 2019; 30: 385-396
        • Ferrara R.
        • Mezquita L.
        • Texier M.
        • et al.
        Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.
        JAMA Oncol. 2018; 4: 1543-1552
        • Champiat S.
        • Dercle L.
        • Ammari S.
        • et al.
        Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1.
        Clin Cancer Res. 2017; 23: 1920-1928
        • Saâda-Bouzid E.
        • Defaucheux C.
        • Karabajakian A.
        • et al.
        Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
        Ann Oncol. 2017; 28: 1605-1611
        • Ferrara R.
        • Signorelli D.
        • Proto C.
        • Prelaj A.
        • Garassino M.C.
        • Lo Russo G.
        Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations.
        Transl Lung Cancer Res. 2021; 10: 2955-2969
        • Therasse P.
        • Arbuck S.G.
        • Eisenhauer E.A.
        • et al.
        New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.
        J Natl Cancer Inst. 2000; 92: 205-216
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Nowak A.K.
        • Chansky K.
        • Rice D.C.
        • et al.
        The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma.
        J Thorac Oncol. 2016; 11: 2089-2099
        • Murphy D.J.
        • Gill R.R.
        Volumetric assessment in malignant pleural mesothelioma.
        Ann Transl Med. 2017; 5: 241
        • Frauenfelder T.
        • Tutic M.
        • Weder W.
        • et al.
        Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?.
        Eur Respir J. 2011; 38: 162-168
        • Pass H.I.
        • Temeck B.K.
        • Kranda K.
        • Steinberg S.M.
        • Feuerstein I.R.
        Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
        J Thorac Cardiovasc Surg. 1998; 115: 310-318
        • Labby Z.E.
        • Nowak A.K.
        • Dignam J.J.
        • Straus C.
        • Kindler H.L.
        • Armato 3rd, S.G.
        Disease volumes as a marker for patient response in malignant pleural mesothelioma.
        Ann Oncol. 2013; 24: 999-1005
        • Liu F.
        • Zhao B.
        • Krug L.M.
        • et al.
        Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computer-aided volumetric measurement on computed tomography scans.
        J Thorac Oncol. 2010; 5: 879-884
        • Armato 3rd, S.G.
        • Li P.
        • Husain A.N.
        • et al.
        Radiologic-pathologic correlation of mesothelioma tumor volume.
        Lung Cancer. 2015; 87: 278-282
        • Labby Z.E.
        • Armato 3rd, S.G.
        • Dignam J.J.
        • Straus C.
        • Kindler H.L.
        • Nowak A.K.
        Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma.
        J Thorac Oncol. 2013; 8: 478-486
        • Sensakovic W.F.
        • Armato 3rd, S.G.
        • Straus C.
        • et al.
        Computerized segmentation and measurement of malignant pleural mesothelioma.
        Med Phys. 2011; 38: 238-244
        • Tsim S.
        • Cowell G.W.
        • Kidd A.
        • et al.
        A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma.
        Lung Cancer. 2020; 150: 12-20
        • Gudmundsson E.
        • Straus C.M.
        • Armato 3rd, S.G.
        Deep convolutional neural networks for the automated segmentation of malignant pleural mesothelioma on computed tomography scans.
        J Med Imaging (Bellingham). 2018; 5034503
        • Kanemura S.
        • Kuribayashi K.
        • Funaguchi N.
        • et al.
        Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
        Eur J Radiol. 2017; 86: 92-98
        • Kitajima K.
        • Maruyama M.
        • Minami T.
        • et al.
        Comparison of modified Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer criteria, and PET Response Criteria in Solid Tumors for evaluation of tumor response to chemotherapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
        Nucl Med Commun. 2020; 41: 790-799
        • Ferdinandus J.
        • Barbato F.
        • Chodyla M.
        • et al.
        Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
        J Nucl Med. 2021; 62: 191-194
        • Kitajima K.
        • Maruyama M.
        • Yokoyama H.
        • et al.
        Response to immune checkpoint inhibitor therapy in patients with unresectable recurrent malignant pleural mesothelioma shown by FDG-PET and CT.
        Cancers (Basel). 2021; 13: 1098
        • Armato 3rd, S.G.
        • Oxnard G.R.
        • MacMahon H.
        • et al.
        Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
        Med Phys. 2004; 31: 1105-1115
        • Armato 3rd, S.G.
        • Oxnard G.R.
        • Kocherginsky M.
        • Vogelzang N.J.
        • Kindler H.L.
        • MacMahon H.
        Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
        Acad Radiol. 2005; 12: 1301-1309
        • Kim H.
        • Goo J.M.
        • Ohno Y.
        • et al.
        Effect of reconstruction parameters on the quantitative analysis of chest computed tomography.
        J Thorac Imaging. 2019; 34: 92-102
        • Sullivan D.C.
        • Obuchowski N.A.
        • Kessler L.G.
        • et al.
        Metrology standards for quantitative imaging biomarkers.
        Radiology. 2015; 277: 813-825
        • Anderson O.
        • Kidd A.
        • Siebert J.
        • et al.
        Fully automated volumetric measurement of malignant pleural mesothelioma from computed tomography images by deep learning: preliminary results of an internal validation.
        in: Proceedings of the 13th International Joint Conference on Biomedical Engineering Systems and Technologies. 2020: 64-73
        • Pavic M.
        • Bogowicz M.
        • Kraft J.
        • et al.
        FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients.
        EJNMMI Res. 2020; 10: 81